메뉴 건너뛰기




Volumn 23, Issue SUPPL. 2, 2010, Pages

Pulmonary formulations: What remains to be done?

Author keywords

controlled release; fixed dose combinations; formulation; innovation; macromolecules; particle engineering

Indexed keywords

DNA; EXCIPIENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GELATIN; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SMALL INTERFERING RNA;

EID: 78650204557     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0838     Document Type: Review
Times cited : (107)

References (190)
  • 3
    • 0001504546 scopus 로고    scopus 로고
    • From Susie's question to CFC free: An inventor's perspective on forty years of MDI development and regu-lation
    • RN Dalby, PR Byron, and SJ Farr (eds) Interpharm Press, Buffalo Grove, IL
    • Thiel CG: From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regu-lation. In: RN Dalby, PR Byron, and SJ Farr (eds). Re-spiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL; pp. 115-123, 1996.
    • (1996) Re-spiratory Drug Delivery v , pp. 115-123
    • Thiel, C.G.1
  • 4
    • 34248639855 scopus 로고    scopus 로고
    • The rejuvenated pressurized me-tered dose inhaler
    • Bell J, and Newman S: The rejuvenated pressurized me-tered dose inhaler. Expert Opin Drug Del. 2007;4:215-234.
    • (2007) Expert Opin Drug Del , vol.4 , pp. 215-234
    • Bell, J.1    Newman, S.2
  • 5
    • 12344288639 scopus 로고    scopus 로고
    • Pulmonary delivery technology: Advances and potential for the new millennium
    • AJ Hickey (ed) Marcel Dekker, New York
    • Clark A: Pulmonary delivery technology: advances and potential for the new millennium. In AJ Hickey (ed). Pharamceutical Inhalation Aerosol Technology, 2nd ed. Marcel Dekker, New York; pp. 571-591, 2004.
    • (2004) Pharamceutical Inhalation Aerosol Technology, 2nd Ed. , pp. 571-591
    • Clark, A.1
  • 9
    • 0011489418 scopus 로고    scopus 로고
    • Dispersion and characterization of pharmaceutical dry powder aerosols
    • Dunbar CA, Hickey AJ, and Holzner P: Dispersion and characterization of pharmaceutical dry powder aerosols. KONA. 1998;16:7-45.
    • (1998) KONA , vol.16 , pp. 7-45
    • Dunbar, C.A.1    Hickey, A.J.2    Holzner, P.3
  • 11
    • 20044363723 scopus 로고    scopus 로고
    • The cohesive-adhesive balances in dry powder inhaler formu-lations I: Direct quantification by atomic force microscopy
    • Begat P, Morton AV, Staniforth JN, and Price R: The cohesive-adhesive balances in dry powder inhaler formu-lations I: direct quantification by atomic force microscopy. Pharm Res. 2004;21:1591-1597.
    • (2004) Pharm Res , vol.21 , pp. 1591-1597
    • Begat, P.1    Morton, A.V.2    Staniforth, J.N.3    Price, R.4
  • 12
    • 6344245649 scopus 로고    scopus 로고
    • The cohesive-adhesive balances in dry powder inhaler formulations II: Influences of fine particle delivery charac-teristics
    • Begat P, Morton AV, Staniforth JN, and Price R: The cohesive-adhesive balances in dry powder inhaler formulations II: influences of fine particle delivery charac-teristics. Pharm Res. 2004;21:1826-1833.
    • (2004) Pharm Res , vol.21 , pp. 1826-1833
    • Begat, P.1    Morton, A.V.2    Staniforth, J.N.3    Price, R.4
  • 13
    • 34248646248 scopus 로고    scopus 로고
    • Design of fine particles for pulmonary drug delivery
    • Weers JG, Tarara TE, and Clark AR: Design of fine particles for pulmonary drug delivery. Expert Opin Drug Del. 2007;4:297-313.
    • (2007) Expert Opin Drug Del , vol.4 , pp. 297-313
    • Weers, J.G.1    Tarara, T.E.2    Clark, A.R.3
  • 14
    • 0034750024 scopus 로고    scopus 로고
    • Use of solid corrugated par-ticles to enhance powder performance
    • Chew NYK, and Chan H-K: Use of solid corrugated par-ticles to enhance powder performance. Pharm Res. 2001;18: 1570-1577.
    • (2001) Pharm Res , vol.18 , pp. 1570-1577
    • Nyk, C.1    Chan, H.-K.2
  • 15
    • 73949099876 scopus 로고    scopus 로고
    • Force control and powder dispersibility of spray dried particles for in-halation
    • Weiler C, Egen M, Trunk M, and Langguth P: Force control and powder dispersibility of spray dried particles for in-halation. J Pharm Sci. 2010;99:303-316.
    • (2010) J Pharm Sci. , vol.99 , pp. 303-316
    • Weiler, C.1    Egen, M.2    Trunk, M.3    Langguth, P.4
  • 17
    • 67649389317 scopus 로고    scopus 로고
    • Porous particles for inhalation: The science be-hind their improved dispersibility
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Dunbar C: Porous particles for inhalation: the science be-hind their improved dispersibility. In RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery X. Amy Davis Biggs, River Grove, IL; pp. 307-313, 2006.
    • (2006) Respiratory Drug Delivery X , pp. 307-313
    • Dunbar, C.1
  • 18
    • 0036803986 scopus 로고    scopus 로고
    • In vitro and in vivo dose delivery charac-teristics of large porous particles for inhalation
    • Dunbar C, Scheuch G, Sommerer K, DeLong M, Verma A, and Batycky R: In vitro and in vivo dose delivery charac-teristics of large porous particles for inhalation. Int J Pharm. 2002; 245:179-189.
    • (2002) Int J Pharm , vol.245 , pp. 179-189
    • Dunbar, C.1    Scheuch, G.2    Sommerer, K.3    Delong, M.4    Verma, A.5    Batycky, R.6
  • 19
    • 29844437915 scopus 로고    scopus 로고
    • Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates
    • DeLong M, Wright J, Dawson M, Meyer T, Sommerer K, and Dunbar C: Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18:452-459.
    • (2005) J Aerosol Med , vol.18 , pp. 452-459
    • Delong, M.1    Wright, J.2    Dawson, M.3    Meyer, T.4    Sommerer, K.5    Dunbar, C.6
  • 22
    • 0028316923 scopus 로고
    • Long term stabilization of biologics
    • Franks F: Long term stabilization of biologics. Bio/Tech-nology. 1994;12:253-256.
    • (1994) Bio/Technology , vol.12 , pp. 253-256
    • Franks, F.1
  • 23
    • 0032817957 scopus 로고    scopus 로고
    • Stabilization of labile materials by amorphous carbohydrates and their derivatives
    • Blair JA, and Hatley RHM: Stabilization of labile materials by amorphous carbohydrates and their derivatives. J Mol Catalysis B: Enzymatic. 1999;7:11-19.
    • (1999) J Mol Catalysis B: Enzymatic , vol.7 , pp. 11-19
    • Blair, J.A.1    Rhm, H.2
  • 24
    • 0037332149 scopus 로고    scopus 로고
    • Micro-calorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids
    • Lechuga-Ballesteros D, Bakri A, and Miller DP: Micro-calorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids. Pharm Res. 2003;20:308-318.
    • (2003) Pharm Res , vol.20 , pp. 308-318
    • Lechuga-Ballesteros, D.1    Bakri, A.2    Miller, D.P.3
  • 26
    • 34248642757 scopus 로고    scopus 로고
    • ^\development of a novel technology solution for pulmonary delivery of insulin
    • RN Dalby, PR Byron, J Peart, and J Suman (eds) Davis Healthcare Int Publishing, LLC, River Grove, IL;
    • ^\ development of a novel technology solution for pulmonary delivery of insulin. In: RN Dalby, PR Byron, J Peart, and J Suman (eds). Respiratory Drug Delivery Europe 2005. Davis Healthcare Int Publishing, LLC, River Grove, IL; pp. 225-227, 2005.
    • (2005) Respiratory Drug Delivery Europe 2005 , pp. 225-227
    • White, S.1    Bennett, D.2    Stevenson, C.3    Harper, N.4
  • 27
    • 0025943936 scopus 로고
    • Contemporary approaches in aerosolized drug delivery to the lung
    • Gupta PK, and Hickey AJ: Contemporary approaches in aerosolized drug delivery to the lung. J Controlled Rel. 1991;17:129-148.
    • (1991) J Controlled Rel , vol.17 , pp. 129-148
    • Gupta, P.K.1    Hickey, A.J.2
  • 28
    • 4544325094 scopus 로고    scopus 로고
    • Controlled release products for respiratory drug delivery
    • Louey MD, and Garcia-Contreas L: Controlled release products for respiratory drug delivery. Am Pharm Rev. 2004;7:82-87.
    • (2004) Am Pharm Rev , vol.7 , pp. 82-87
    • Louey, M.D.1    Garcia-Contreas, L.2
  • 29
    • 0022539757 scopus 로고
    • Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation
    • Byron PR: Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75:433-438.
    • (1986) J Pharm Sci , vol.75 , pp. 433-438
    • Byron, P.R.1
  • 30
    • 0029090267 scopus 로고
    • The controlled de-livery of drugs to the lung
    • Zeng, XM, Martin GP, and Marriott C: The controlled de-livery of drugs to the lung. Int J Pharm. 1995;124:149-164.
    • (1995) Int J Pharm , vol.124 , pp. 149-164
    • Zeng, X.M.1    Martin, G.P.2    Marriott, C.3
  • 31
    • 0033925098 scopus 로고    scopus 로고
    • Sustained drug delivery to the lungs\an option for the future
    • Hardy JG, and Chadwick TS: Sustained drug delivery to the lungs\an option for the future. Clin Pharmacokinet. 2000;39:1-4.
    • (2000) Clin Pharmacokinet , vol.39 , pp. 1-4
    • Hardy, J.G.1    Chadwick, T.S.2
  • 32
    • 0034848118 scopus 로고    scopus 로고
    • Respirable PLGA micro-spheres containing rifampicin for the treatment of tuber-culosis: Screening in an infectious disease model
    • Suarez S, O'Hara P, Kazantseva M, Newcomer C, Hopfer R, McMurray DN, and Hickey AJ: Respirable PLGA micro-spheres containing rifampicin for the treatment of tuber-culosis: screening in an infectious disease model. Pharm Res. 2001;18:1315-1319.
    • (2001) Pharm Res , vol.18 , pp. 1315-1319
    • Suarez, S.1    O'Hara, P.2    Kazantseva, M.3    Newcomer, C.4    Hopfer, R.5    McMurray, D.N.6    Hickey, A.J.7
  • 36
    • 77955903375 scopus 로고    scopus 로고
    • Technosphere insulin: Defining the role of Technosphere particles at the cellular level
    • Angelo R, Rousseau K, Grant M, Leone-Bay A, and Ri-chardson P: Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2009;3:545-554.
    • (2009) J Diabetes Sci Technol , vol.3 , pp. 545-554
    • Angelo, R.1    Rousseau, K.2    Grant, M.3    Leone-Bay, A.4    Ri-Chardson, P.5
  • 38
    • 17444378903 scopus 로고    scopus 로고
    • Dry powder for pulmonary delivery of peptides and proteins
    • Okamoto H, Todo H, Iida K, and Danjo K: Dry powder for pulmonary delivery of peptides and proteins. Kona. 2002;20:71-83.
    • (2002) Kona , vol.20 , pp. 71-83
    • Okamoto, H.1    Todo, H.2    Iida, K.3    Danjo, K.4
  • 39
    • 33750700160 scopus 로고    scopus 로고
    • Transport of aerosolized IL-2 chimeric protein using polymeric immu-noglobulin receptor in the lung
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Sacaan AI, Edwards WR, Domingo D, et al.: Transport of aerosolized IL-2 chimeric protein using polymeric immu-noglobulin receptor in the lung. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 357-360, 2004.
    • (2004) Respiratory Drug Delivery IX , pp. 357-360
    • Sacaan, A.I.1    Edwards, W.R.2    Domingo, D.3
  • 40
    • 25844519559 scopus 로고    scopus 로고
    • Antibody trans-porters\are they usable carriers for biopharmaceuticals?
    • RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Bitonti A, Dumont J, Garcia AM, et al.: Antibody trans-porters\are they usable carriers for biopharmaceuticals? In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 79-85, 2004.
    • (2004) Respiratory Drug Delivery IX , pp. 79-85
    • Bitonti, A.1    Dumont, J.2    Garcia, A.M.3
  • 42
    • 21744451528 scopus 로고    scopus 로고
    • Modifying the pul-monary absorption and retention of proteins through PE-Gylation
    • RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Leach CI, Kuo M-C, Bueche B, et al.: Modifying the pul-monary absorption and retention of proteins through PE-Gylation. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 69-77, 2004.
    • (2004) Respiratory Drug Delivery IX , pp. 69-77
    • Leach, C.I.1    Kuo, M.-C.2    Bueche, B.3
  • 43
    • 0023131314 scopus 로고
    • Comparison of physical and inhalation properties of spray-dried and me-chanically micronized sodium cromoglycate
    • Vidgren MT, Vidgren PA, and Panonen TP: Comparison of physical and inhalation properties of spray-dried and me-chanically micronized sodium cromoglycate. Int J Pharm. 1987; 35:139-144.
    • (1987) Int J Pharm , vol.35 , pp. 139-144
    • Vidgren, M.T.1    Vidgren, P.A.2    Panonen, T.P.3
  • 44
    • 0031393964 scopus 로고    scopus 로고
    • The effect of operating and formulation variables on the mor-phology of spray-dried protein particles
    • Maa YF, Constantino HR, Nguyen PA, and Hsu CC: The effect of operating and formulation variables on the mor-phology of spray-dried protein particles. Pharm Dev Technol. 1997;2:213-223.
    • (1997) Pharm Dev Technol , vol.2 , pp. 213-223
    • Maa, Y.F.1    Constantino, H.R.2    Nguyen, P.A.3    Hsu, C.C.4
  • 45
    • 42049094490 scopus 로고    scopus 로고
    • Pharmaceutical particle engineering via spray-drying
    • Vehring R: Pharmaceutical particle engineering via spray-drying. Pharm Res. 2008;25:999-1022.
    • (2008) Pharm Res , vol.25 , pp. 999-1022
    • Vehring, R.1
  • 47
    • 42049100251 scopus 로고    scopus 로고
    • Embedded crystals in low density particles: Formulation, manufacture, and properties
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Tarara T, Malcolmson R, Leung D, and Weers J: Embedded crystals in low density particles: formulation, manufacture, and properties. In RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery X. Amy Davis Biggs, River Grove, IL; pp. 297-304, 2006.
    • (2006) Respiratory Drug Delivery X , pp. 297-304
    • Tarara, T.1    Malcolmson, R.2    Leung, D.3    Weers, J.4
  • 49
    • 33750804217 scopus 로고    scopus 로고
    • Particle engineering tech-niques for inhaled biopharmaceuticals
    • Shoyele SA, and Cawthorne S: Particle engineering tech-niques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-1029.
    • (2006) Adv Drug Deliv Rev , vol.58 , pp. 1009-1029
    • Shoyele, S.A.1    Cawthorne, S.2
  • 50
    • 33646896501 scopus 로고    scopus 로고
    • Formulation and charac-terization of lipid-coated tobramycin particles for dry powder inhalation
    • Pilcer G, Sebti T, and Amighi K: Formulation and charac-terization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res. 2006;23:931-940.
    • (2006) Pharm Res , vol.23 , pp. 931-940
    • Pilcer, G.1    Sebti, T.2    Amighi, K.3
  • 51
    • 2442666256 scopus 로고    scopus 로고
    • A novel spray-drying technique to produce low density particles for pulmonary delivery
    • Steckl H, and Brandes HG: A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm. 2004;278:187-195.
    • (2004) Int J Pharm , vol.278 , pp. 187-195
    • Steckl, H.1    Brandes, H.G.2
  • 54
    • 33847127477 scopus 로고    scopus 로고
    • Particle engineering for pulmonary drug delivery
    • Chow AHL, Tong HHY, Chattopadhyay P, and Shekunov BY: Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411-437.
    • (2007) Pharm Res , vol.24 , pp. 411-437
    • Ahl, C.1    Hhy, T.2    Chattopadhyay, P.3    Shekunov, B.Y.4
  • 55
    • 33947287573 scopus 로고    scopus 로고
    • Drying-induced variations in physicochemical properties of amorphous pharmaceuti-cals and their impact on stability (I): Stability of a mono-clonal antibody
    • Abdul-Fattah AM, Truong-Le V, Yee L, Nguyen L, Kalonia DS, Cicerone MT, and Pikal MJ: Drying-induced variations in physicochemical properties of amorphous pharmaceuti-cals and their impact on stability (I): stability of a mono-clonal antibody. J Pharm Sci. 2007;96:1983-2008.
    • (2007) J Pharm Sci , vol.96 , pp. 1983-2008
    • Abdul-Fattah, A.M.1    Truong-Le, V.2    Yee, L.3    Nguyen, L.4    Kalonia, D.S.5    Cicerone, M.T.6    Pikal, M.J.7
  • 56
    • 0000425854 scopus 로고    scopus 로고
    • Particle engineering by supercritical fluid technologies for powder inhalation drug delivery
    • PR Byron, RN Dalby, and SJ Farr (eds) Interpharm Press, Buffalo Grove, IL
    • York P, and Hanna M: Particle engineering by supercritical fluid technologies for powder inhalation drug delivery. In: PR Byron, RN Dalby, and SJ Farr (eds). Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL; pp. 231-239, 1996.
    • (1996) Respiratory Drug Delivery v , pp. 231-239
    • York, P.1    Hanna, M.2
  • 57
    • 0033365877 scopus 로고    scopus 로고
    • Formation of small droplet aerosols assisted by supercritical carbon dioxide
    • Sievers RE, Karst U, Milewski PD, et al.: Formation of small droplet aerosols assisted by supercritical carbon dioxide. Aerosol Sci Technol. 1999;30:3-15.
    • (1999) Aerosol Sci Technol , vol.30 , pp. 3-15
    • Sievers, R.E.1    Karst, U.2    Milewski, P.D.3
  • 58
    • 70449088928 scopus 로고    scopus 로고
    • Engineering of crystalline combination inhalation particles of a long-acting beta-2 agonist and a corticosteroid
    • Pitchayajittipong C, Shur J, and Price R: Engineering of crystalline combination inhalation particles of a long-acting beta-2 agonist and a corticosteroid. Pharm Res. 2009;26: 2657-2666.
    • (2009) Pharm Res , vol.26 , pp. 2657-2666
    • Pitchayajittipong, C.1    Shur, J.2    Price, R.3
  • 59
    • 39749100131 scopus 로고    scopus 로고
    • Preparation of inhalable salbutamol sulfate using reactive high gravity controlled precipitation
    • Hu TT, Chiou H, Chan H-K, Chen J-F, and Yun J: Preparation of inhalable salbutamol sulfate using reactive high gravity controlled precipitation. J Pharm Sci. 2008;97:944-949.
    • (2008) J Pharm Sci , vol.97 , pp. 944-949
    • Hu, T.T.1    Chiou, H.2    Chan, H.-K.3    Chen, J.-F.4    Yun, J.5
  • 60
    • 43649096146 scopus 로고    scopus 로고
    • A novel production method for inhalable cyclosporin A powders by confined liquid impinging jet precipitation
    • Chiou H, Chan H-K, Heng D, Prud'Homme RK, and Raper JA: A novel production method for inhalable cyclosporin A powders by confined liquid impinging jet precipitation. J Aerosol Sci. 2008;39:500-509.
    • (2008) J Aerosol Sci , vol.39 , pp. 500-509
    • Chiou, H.1    Chan, H.-K.2    Heng, D.3    Prud'Homme, R.K.4    Raper, J.A.5
  • 64
    • 33645413962 scopus 로고    scopus 로고
    • High dose inhaled powder delivery-challenges and techniques
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Weers J, Clark A, and Challoner P: High dose inhaled powder delivery-challenges and techniques. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 357-360, 2004.
    • (2004) Respiratory Drug Delivery IX , pp. 357-360
    • Weers, J.1    Clark, A.2    Challoner, P.3
  • 65
    • 34247193128 scopus 로고    scopus 로고
    • Novel tobramycin inhalation powder in cystic fi-brosis subjects: Pharmacokinetics and safety
    • Geller DE, Konstan MW, Smith J, Noonberg SB, and Con-rad C: Novel tobramycin inhalation powder in cystic fi-brosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307-313.
    • (2007) Pediatr Pulmonol , vol.42 , pp. 307-313
    • De, G.1    Konstan, M.W.2    Smith, J.3    Noonberg, S.B.4    Con-Rad, C.5
  • 66
    • 33847777944 scopus 로고    scopus 로고
    • Dry powder inhalation versus wet nebulization delivery of antibiotics in cystic fibrosis patients
    • Westerman EM, Heijerman HG, and Frijlink HW: Dry powder inhalation versus wet nebulization delivery of antibiotics in cystic fibrosis patients. Exp Opin Drug Del. 2007;4:91-94.
    • (2007) Exp Opin Drug Del , vol.4 , pp. 91-94
    • Westerman, E.M.1    Heijerman, H.G.2    Frijlink, H.W.3
  • 67
    • 70350228508 scopus 로고    scopus 로고
    • Inhaled drug delivery for tuberculosis therapy
    • Muttil P, Wang C, and Hickey AJ: Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401-2416.
    • (2009) Pharm Res , vol.26 , pp. 2401-2416
    • Muttil, P.1    Wang, C.2    Hickey, A.J.3
  • 70
    • 33748691353 scopus 로고    scopus 로고
    • In-situ coating: An approach for particle modification and encapsulation of proteins during spray-drying
    • Elversson J, and Millqvist-Fureby A: In-situ coating: an approach for particle modification and encapsulation of proteins during spray-drying. Int J Pharm 2006;323:52-63.
    • (2006) Int J Pharm , vol.323 , pp. 52-63
    • Elversson, J.1    Millqvist-Fureby, A.2
  • 71
    • 33846076698 scopus 로고    scopus 로고
    • Degree of throat deposition can explain the variability in lung deposition of inhaled drugs
    • Börgstrom L, Olsson B, and Thorsson L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-483.
    • (2006) J Aerosol Med , vol.19 , pp. 473-483
    • Börgstrom, L.1    Olsson, B.2    Thorsson, L.3
  • 73
    • 78650192172 scopus 로고    scopus 로고
    • Effects of device design on patient compliance: Comparing the same drug in different devices. in
    • RN Dalby, PR Byron, J Peart, and JD Suman (eds) Davis Healthcare, River Grove, IL
    • Chrystyn H: Effects of device design on patient compliance: comparing the same drug in different devices. In: RN Dalby, PR Byron, J Peart, and JD Suman (eds). Respiratory Drug Delivery Europe 2009. Davis Healthcare, River Grove, IL; pp. 105-116, 2009.
    • Respiratory Drug Delivery Europe 2009 , vol.2009 , pp. 105-116
    • Chrystyn, H.1
  • 74
    • 0034864138 scopus 로고    scopus 로고
    • Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity
    • Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, and Witnek TJ: Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309-315.
    • (2001) J Aerosol Med , vol.14 , pp. 309-315
    • Chodosh, S.1    Flanders, J.S.2    Kesten, S.3    Serby, C.W.4    Hochrainer, D.5    Witnek, T.J.6
  • 75
    • 77955421503 scopus 로고    scopus 로고
    • Concept 1 (a single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients
    • RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare, River Grove, IL
    • Pavkov R, Singh D, and Reitveld I: Concept 1 (a single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2008. Davis Healthcare, River Grove, IL; pp. 683-686, 2008.
    • Respiratory Drug Delivery 2008 , vol.2008 , pp. 683-686
    • Pavkov, R.1    Singh, D.2    Reitveld, I.3
  • 76
    • 78650224939 scopus 로고    scopus 로고
    • Beyond the throat: Preferred methods of asses-sing regional distribution in the lung
    • RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare Interna-tional Publishing, River Grove, IL
    • Clark AR: Beyond the throat: Preferred methods of asses-sing regional distribution in the lung. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2010. Davis Healthcare Interna-tional Publishing, River Grove, IL; pp. 235-244, 2010.
    • (2010) Respiratory Drug Delivery 2010 , pp. 235-244
    • Clark, A.R.1
  • 77
    • 0027937427 scopus 로고
    • The new ICRP model for the respiratory tract
    • Bailey MR: The new ICRP model for the respiratory tract. Radiat Protein Dosim. 1994;53:107-114.
    • (1994) Radiat Protein Dosim , vol.53 , pp. 107-114
    • Bailey, M.R.1
  • 80
    • 1142309474 scopus 로고    scopus 로고
    • Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controlled therapies
    • Stoloff SW, Stempel DA, Meyer T, Stanford RH, and Car-ranza Rosenzweig JR: Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controlled therapies. J Allergy Clin Immunol. 2004;113:245-251.
    • (2004) J Allergy Clin Immunol , vol.113 , pp. 245-251
    • Stoloff, S.W.1    Stempel, D.A.2    Meyer, T.3    Stanford, R.H.4    Car-Ranza Rosenzweig, J.R.5
  • 81
    • 0037999825 scopus 로고    scopus 로고
    • Enhanced synergy between fluticasone pro-pionate and salmeterol inhaled from a single inhaler versus separate inhalers
    • Nelson HS, Chapman KR, Pyke SD, Johnson M, and Pritchard JN: Enhanced synergy between fluticasone pro-pionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29-36.
    • (2003) J Allergy Clin Immunol , vol.112 , pp. 29-36
    • Nelson, H.S.1    Chapman, K.R.2    Pyke, S.D.3    Johnson, M.4    Pritchard, J.N.5
  • 82
    • 14744303633 scopus 로고    scopus 로고
    • Combination therapy of long-acting beta ago-nists and inhaled corticosteroids in the management of chronic asthma
    • Nelson HS: Combination therapy of long-acting beta ago-nists and inhaled corticosteroids in the management of chronic asthma. Curr Allergy Asthma Rep. 2005;5:123-129.
    • (2005) Curr Allergy Asthma Rep , vol.5 , pp. 123-129
    • Nelson, H.S.1
  • 83
    • 33846564005 scopus 로고    scopus 로고
    • Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?
    • Sin DD, and Man SFP: Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulmon Med. 2007;13:90-97.
    • (2007) Curr Opin Pulmon Med , vol.13 , pp. 90-97
    • Sin, D.D.1    Sfp, M.2
  • 84
    • 33845418508 scopus 로고    scopus 로고
    • Asthma related ED/hospitalization risk and asthma costs of fluticasone propi-onate/salmeterol in a single inhaler compared to flutica-sone propionate and salmeterol in separate inhalers
    • Stempel DA, Stanford RH, and Kim T: Asthma related ED/hospitalization risk and asthma costs of fluticasone propi-onate/salmeterol in a single inhaler compared to flutica-sone propionate and salmeterol in separate inhalers. J Allergy Clin Immunol. 2004;113(Suppl):S272.
    • (2004) J Allergy Clin Immunol , vol.113 , Issue.SUPPL.
    • Stempel, D.A.1    Stanford, R.H.2    Kim, T.3
  • 85
    • 0036153433 scopus 로고    scopus 로고
    • Scientific rationale for inhaled combination therapy with long-acting beta(2)-agonists and corticoste-roids
    • Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting beta(2)-agonists and corticoste-roids. Eur Respir J. 2002;19:182-191.
    • (2002) Eur Respir J , vol.19 , pp. 182-191
    • Barnes, P.J.1
  • 86
    • 77951205795 scopus 로고    scopus 로고
    • Overcoming the challenges of developing combination products in different inhalation device platforms
    • Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, and Young PM (eds) Davis Healthcare Intl Publ, River Grove, IL
    • Hannay M, Govind N, Ludzik A, Jansen R, and Fletcher I: Overcoming the challenges of developing combination products in different inhalation device platforms. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, and Young PM (eds). Respiratory Drug Delivery 2008. Davis Healthcare Intl Publ, River Grove, IL; pp. 319-328, 2008.
    • Respiratory Drug Delivery 2008 , vol.2008 , pp. 319-328
    • Hannay, M.1    Govind, N.2    Ludzik, A.3    Jansen, R.4    Fletcher, I.5
  • 87
    • 78650197961 scopus 로고    scopus 로고
    • An assess-ment of the in vitro deposition of aerosolized drugs from a combination dry powder inhaler using the Andersen cascade impactor (ACI)
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Davis Healthcare, River Grove, IL
    • Taki M, Zeng XM, Marriott C, and Martin G: An assess-ment of the in vitro deposition of aerosolized drugs from a combination dry powder inhaler using the Andersen cascade impactor (ACI). In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery 2006. Davis Healthcare, River Grove, IL; pp. 655-657, 2006.
    • Respiratory Drug Delivery 2006 , vol.2006 , pp. 655-657
    • Taki, M.1    Zeng, X.M.2    Marriott, C.3    Martin, G.4
  • 88
    • 0031001329 scopus 로고    scopus 로고
    • Variations in the adhesion force between a drug and carrier particles as a result of changes in the relative humidity of the air
    • Podezcek F, Newton JM, and James MB: Variations in the adhesion force between a drug and carrier particles as a result of changes in the relative humidity of the air. Int J Pharm. 1997;149:151-160.
    • (1997) Int J Pharm , vol.149 , pp. 151-160
    • Podezcek, F.1    Newton, J.M.2    James, M.B.3
  • 89
    • 33644617924 scopus 로고    scopus 로고
    • Dry powder inhaler formula-tions
    • Telko MJ, and Hickey AJ: Dry powder inhaler formula-tions. Respir Care. 2005;9:1209-1220.
    • (2005) Respir Care , vol.9 , pp. 1209-1220
    • Telko, M.J.1    Hickey, A.J.2
  • 90
    • 78650205640 scopus 로고    scopus 로고
    • Unit dose level particle size distribution characterization of combi-nation drug inhalation product
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Davis Healthcare, River Grove, IL
    • Menzeleev R, Derrien Y, Bovet J, and Hickey AJ: Unit dose level particle size distribution characterization of combi-nation drug inhalation product. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery 2006, Davis Healthcare, River Grove, IL; pp. 585-588, 2006.
    • Respiratory Drug Delivery 2006 , vol.2006 , pp. 585-588
    • Menzeleev, R.1    Derrien, Y.2    Bovet, J.3    Hickey, A.J.4
  • 91
    • 78650217670 scopus 로고    scopus 로고
    • Production-scale optimization of the manufacturing process for HFA-134a metered dose inhaler containing both salmeterol (SAL) and fluticasone propionate (FP)
    • Duquemin SJ, Ashurst IC, Burke AL, et al.: Production-scale optimization of the manufacturing process for HFA-134a metered dose inhaler containing both salmeterol (SAL) and fluticasone propionate (FP). Proceedings from Drug Delivery to the Lungs VIII, 1997.
    • (1997) Proceedings from Drug Delivery to the Lungs VIII
    • Duquemin, S.J.1    Ashurst, I.C.2    Burke, A.L.3
  • 93
    • 0035912936 scopus 로고    scopus 로고
    • Char-acterization of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system
    • Snowden MY, Chowdhry BZ, Ashurst IC, et al,: Char-acterization of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system. Int J Pharm. 2001;221:165-174.
    • (2001) Int J Pharm , vol.221 , pp. 165-174
    • Snowden, M.Y.1    Chowdhry, B.Z.2    Ashurst, I.C.3
  • 94
    • 70449129733 scopus 로고    scopus 로고
    • The influence of flow rate on the aerosol deposition profile and electro-static charge of single and combination metered dose in-halers
    • Hoe S, Traini D, Chan H-K, and Young PM: The influence of flow rate on the aerosol deposition profile and electro-static charge of single and combination metered dose in-halers. Pharm Res. 2009;26:2639-2646.
    • (2009) Pharm Res , vol.26 , pp. 2639-2646
    • Hoe, S.1    Traini, D.2    Chan, H.-K.3    Young, P.M.4
  • 98
    • 84868140484 scopus 로고    scopus 로고
    • Co-deposition of albuterol sulfate, ipratropium bromide co-crystal aerosols
    • RN Dalby, PR Byron, J Peart, and JD Suman (eds) Davis Healthcare, River Grove, IL
    • Jin F, Hindle M, and Byron P: Co-deposition of albuterol sulfate, ipratropium bromide co-crystal aerosols. In: RN Dalby, PR Byron, J Peart, and JD Suman (eds). Respiratory Drug Delivery Europe 2007. Davis Healthcare, River Grove, IL; pp. 373-376, 2007.
    • Respiratory Drug Delivery Europe 2007 , vol.2007 , pp. 373-376
    • Jin, F.1    Hindle, M.2    Byron, P.3
  • 101
    • 67349131897 scopus 로고    scopus 로고
    • Combination chemothera-peutic dry powder aerosols via controlled nanoparticle agglomeration
    • El-Gendy N, and Berkland C: Combination chemothera-peutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009;26:1752-1763.
    • (2009) Pharm Res , vol.26 , pp. 1752-1763
    • El-Gendy, N.1    Berkland, C.2
  • 102
    • 49249105173 scopus 로고    scopus 로고
    • Combination particles con-taining salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment
    • Westmeier R, and Steckel H: Combination particles con-taining salmeterol xinafoate and fluticasone propionate: formulation and aerodynamic assessment. J Pharm Sci. 2008; 97:2299-2310.
    • (2008) J Pharm Sci , vol.97 , pp. 2299-2310
    • Westmeier, R.1    Steckel, H.2
  • 103
    • 33748306274 scopus 로고    scopus 로고
    • Physicochem-ical and in vitro deposition properties of salbutamol sul-phate/impratropium bromide and salbutamol sulphate/excipient spray-dried mixtures for use in dry powder in-halers
    • Corrigan DO, Corrigan OI, and Healy AM: Physicochem-ical and in vitro deposition properties of salbutamol sul-phate/impratropium bromide and salbutamol sulphate/excipient spray-dried mixtures for use in dry powder in-halers. Int J Pharm. 2006;322:22-30.
    • (2006) Int J Pharm , vol.322 , pp. 22-30
    • Corrigan, D.O.1    Corrigan, O.I.2    Healy, A.M.3
  • 106
    • 58249116658 scopus 로고    scopus 로고
    • Spray drying of budesonide, formoterol fumarate and their composites\1. Physicochemical characterization
    • Tajber L, Corrigan DO, Corrigan OI, and Healy AM: Spray drying of budesonide, formoterol fumarate and their composites\1. Physicochemical characterization. Int J Pharm. 2009;367:79-85.
    • (2009) Int J Pharm , vol.367 , pp. 79-85
    • Tajber, L.1    Corrigan, D.O.2    Corrigan, O.I.3    Healy, A.M.4
  • 107
    • 58249113923 scopus 로고    scopus 로고
    • Spray drying of budesonide, formoterol fumarate and their composites II. Statistical factorial design and in vitro deposition proper-ties
    • Tajber L, Corrigan OI, and Healy AM: Spray drying of budesonide, formoterol fumarate and their composites II. Statistical factorial design and in vitro deposition proper-ties. Int J Pharm. 2009;367:86-96.
    • (2009) Int J Pharm , vol.367 , pp. 86-96
    • Tajber, L.1    Corrigan, O.I.2    Healy, A.M.3
  • 108
    • 64149102365 scopus 로고    scopus 로고
    • Sustained delivery by leucine-modifed chitosan spray-dried respira-ble powders
    • Learoyd TP, Burrows JL, French E, and Seville P: Sustained delivery by leucine-modifed chitosan spray-dried respira-ble powders. Int J Pharm. 2009; 372:97-104.
    • (2009) Int J Pharm , vol.372 , pp. 97-104
    • Learoyd, T.P.1    Burrows, J.L.2    French, E.3    Seville, P.4
  • 109
    • 72949104558 scopus 로고    scopus 로고
    • Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and cipro-floxacin for treatment of cystic fibrosis
    • Yang Y, Tsifansky MD, Wu C-J, Yang HI, Schmidt G, and Yeo Y: Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and cipro-floxacin for treatment of cystic fibrosis. Pharm Res. 2010; 27:151-160
    • (2010) Pharm Res. , vol.27 , pp. 151-160
    • Yang, Y.1    Tsifansky, M.D.2    Wu, C.-J.3    Yang, H.I.4    Schmidt, G.5    Yeo, Y.6
  • 110
    • 77951207948 scopus 로고    scopus 로고
    • Can low-dose combination products for inhalation be formu-lated in single crystalline particles?
    • Kumon M, Kwok PCL, Adi H, Heng D, and Chan H-K: Can low-dose combination products for inhalation be formu-lated in single crystalline particles? Eur J Pharm Sci. 2010; 40:16-24.
    • (2010) Eur J Pharm Sci. , vol.40 , pp. 16-24
    • Kumon, M.1    Pcl, K.2    Adi, H.3    Heng, D.4    Chan, H.-K.5
  • 112
    • 0015425028 scopus 로고
    • Absorption of drugs from the rat lung
    • Enna SJ, and Schanker LS: Absorption of drugs from the rat lung. Am J Physiol. 1972;223:1227-1231.
    • (1972) Am J Physiol , vol.223 , pp. 1227-1231
    • Enna, S.J.1    Schanker, L.S.2
  • 113
    • 26944439522 scopus 로고    scopus 로고
    • The lungs as a portal of entry for systemic drug delivery
    • Patton JS, Fishburn CS, and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thor Soc. 2004;1:338-344.
    • (2004) Proc Am Thor Soc , vol.1 , pp. 338-344
    • Patton, J.S.1    Fishburn, C.S.2    Weers, J.G.3
  • 115
    • 0027984419 scopus 로고
    • Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae Staphylococcus aureus and Pseudomonas aeruginosa for which MICs are similar
    • Hyatt JM, Nix DE, and Schentag JJ: Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Anti-microb Agents Chemother. 1994;38:2730-2737.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 2730-2737
    • Hyatt, J.M.1    De, N.2    Schentag, J.J.3
  • 116
    • 1642313902 scopus 로고    scopus 로고
    • Liposome delivery of ciprofloxacin against intracellular Francisella tularensis in-fection
    • Wong JP, Yang H, and Blasetti KL: Liposome delivery of ciprofloxacin against intracellular Francisella tularensis in-fection. J Control Rel. 2003; 92:265-273.
    • (2003) J Control Rel , vol.92 , pp. 265-273
    • Wong, J.P.1    Yang, H.2    Blasetti, K.L.3
  • 119
  • 121
    • 0022456536 scopus 로고
    • Preparation, characterization, and controlled release from coprecipitates of fluorescein and magnesium hydroxide
    • Hickey AJ, and Byron PR: Preparation, characterization, and controlled release from coprecipitates of fluorescein and magnesium hydroxide. J Pharm Sci. 1986; 75:756-759.
    • (1986) J Pharm Sci , vol.75 , pp. 756-759
    • Hickey, A.J.1    Byron, P.R.2
  • 122
    • 0033795452 scopus 로고    scopus 로고
    • Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization
    • O'Hara P, and Hickey AJ: Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17: 955-961.
    • (2000) Pharm Res , vol.17 , pp. 955-961
    • O'Hara, P.1    Hickey, A.J.2
  • 123
    • 78650193027 scopus 로고    scopus 로고
    • Inhaled liposomal cipro-floxacin: In vitro properties and aerosol performance
    • RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare Intl Publishing LLC, River Grove, IL
    • Cipolla DC, Dayton F, Fulzele S, Gabatan E, Mudumba S, Yim D, Wu H, and Zwolinski R. Inhaled liposomal cipro-floxacin: in vitro properties and aerosol performance. In RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2010. Davis Healthcare Intl Publishing LLC, River Grove, IL; pp. 409-414, 2010.
    • (2010) Respiratory Drug Delivery 2010 , pp. 409-414
    • Cipolla, D.C.1    Dayton, F.2    Fulzele, S.3    Gabatan, E.4    Mudumba, S.5    Yim, D.6    Wu, H.7    Zwolinski, R.8
  • 124
    • 78650214408 scopus 로고    scopus 로고
    • Mu-dumbaS, and GondaI. Inhaled liposomal ciprofloxacin: Once a day management ofrespiratory infections
    • RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds) Davis Healthcare Intl Publishing LLC, River Grove, IL
    • Bruinenberg P, Blanchard JD, Cipolla DC, Dayton F, Mu-dumbaS, and GondaI. Inhaled liposomal ciprofloxacin: once a day management ofrespiratory infections. In RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Re-spiratory Drug Delivery 2010. Davis Healthcare Intl Publishing LLC, River Grove, IL; pp. 73-81, 2010.
    • (2010) Re-spiratory Drug Delivery 2010 , pp. 73-81
    • Bruinenberg, P.1    Blanchard, J.D.2    Cipolla, D.C.3    Dayton, F.4
  • 129
    • 64749110689 scopus 로고    scopus 로고
    • Recent advances in liposomal dry powder formulations: Preparation and evaluation
    • Misra A, Jinturkar K, Patel D, Lalani J, and Chougule M: Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin Drug Deliv. 2009;6:71-89.
    • (2009) Expert Opin Drug Deliv , vol.6 , pp. 71-89
    • Misra, A.1    Jinturkar, K.2    Patel, D.3    Lalani, J.4    Chougule, M.5
  • 133
    • 58849089005 scopus 로고    scopus 로고
    • Nanoparticle formulations in pulmonary drug delivery
    • Bailey MM, and Berkland CJ: Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29:196-212.
    • (2009) Med Res Rev , vol.29 , pp. 196-212
    • Bailey, M.M.1    Berkland, C.J.2
  • 134
    • 0037426696 scopus 로고    scopus 로고
    • Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nano-particle characteristics on aerosol features
    • Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, and Kissel T: Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nano-particle characteristics on aerosol features. J Control Release. 2003;86:131-144.
    • (2003) J Control Release , vol.86 , pp. 131-144
    • Dailey, L.A.1    Schmehl, T.2    Gessler, T.3    Wittmar, M.4    Grimminger, F.5    Seeger, W.6    Kissel, T.7
  • 135
    • 70350228508 scopus 로고    scopus 로고
    • Inhaled drug delivery for tuberculosis therapy
    • Muttil P, Wang C, and Hickey AJ: Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401-2416.
    • (2009) Pharm Res , vol.26 , pp. 2401-2416
    • Muttil, P.1    Wang, C.2    Hickey, A.J.3
  • 137
    • 0028407436 scopus 로고
    • Controlled release from condensation-coated respirable aerosol parti-cles
    • Pillai RS, Yeates DB, Miller IF, and Hickey AJ: Controlled release from condensation-coated respirable aerosol parti-cles. J Aerosol Sci. 1994;25:461-477.
    • (1994) J Aerosol Sci , vol.25 , pp. 461-477
    • Pillai, R.S.1    Yeates, D.B.2    Miller, I.F.3    Hickey, A.J.4
  • 138
    • 0031913877 scopus 로고    scopus 로고
    • Controlled dissolution from wax-coated aerosol particles in canine lungs
    • Pillai RS, Yeates DB, Miller IF, and Hickey AJ: Controlled dissolution from wax-coated aerosol particles in canine lungs. J Applied Physiol. 1998;84:717-725.
    • (1998) J Applied Physiol , vol.84 , pp. 717-725
    • Pillai, R.S.1    Yeates, D.B.2    Miller, I.F.3    Hickey, A.J.4
  • 139
    • 33747087794 scopus 로고    scopus 로고
    • Manufacture, characterization, and pharmacodynamic evaluation of en-gineered ipratropium bromide particles
    • Taylor MK, Hickey AJ, and van Oort MM: Manufacture, characterization, and pharmacodynamic evaluation of en-gineered ipratropium bromide particles. Pharm Dev Tech-nol. 2006;11:321-336.
    • (2006) Pharm Dev Tech-nol , vol.11 , pp. 321-336
    • Taylor, M.K.1    Hickey, A.J.2    Van Oort, M.M.3
  • 140
    • 78650182767 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmaco-dynamic aspectsofinhaled therapeutic
    • T Martonen (ed) WIT Press, Southampton, UK
    • Suarez S, and Hickey AJ: Pharmacokinetic and pharmaco-dynamic aspectsofinhaled therapeutic agents. In: T Martonen (ed). Medical Applications of Computer Modeling: The Respiratory System. WIT Press, Southampton, UK; pp. 225-304, 2001.
    • (2001) Medical Applications of Computer Modeling: The Respiratory System , pp. 225-304
    • Suarez, S.1    Hickey, A.J.2
  • 141
    • 51549109127 scopus 로고    scopus 로고
    • The gui-nea pig as a model of infectious diseases
    • Padilla-Carlin D, McMurray DN, and Hickey AJ: The gui-nea pig as a model of infectious diseases. Comp Med. 2008;58:324-340.
    • (2008) Comp Med , vol.58 , pp. 324-340
    • Padilla-Carlin, D.1    McMurray, D.N.2    Hickey, A.J.3
  • 142
    • 14644428751 scopus 로고    scopus 로고
    • Inertial aerosol deposition at the surface of airway epithelial cell monolayers
    • Kazantseva M, and Hickey AJ: Inertial aerosol deposition at the surface of airway epithelial cell monolayers. Pharm Sci. 1998;1:S656.
    • (1998) Pharm Sci , vol.1
    • Kazantseva, M.1    Hickey, A.J.2
  • 143
    • 14644387257 scopus 로고    scopus 로고
    • Development of a lung model utilizing human alveolar epithelial cells for evaluating aerosol drug delivery
    • RN Dalby, PR Byron, J Peart, and SJ Farr (eds) Davis Horwood Publishing, Raleigh, NC
    • Kazantseva M, Cooney D, and Hickey AJ: Development of a lung model utilizing human alveolar epithelial cells for evaluating aerosol drug delivery. In: RN Dalby, PR Byron, J Peart, and SJ Farr (eds). Respiratory Drug Delivery VIII. Davis Horwood Publishing, Raleigh, NC; pp. 707-710, 2002.
    • (2002) Respiratory Drug Delivery VIII , pp. 707-710
    • Kazantseva, M.1    Cooney, D.2    Hickey, A.J.3
  • 144
    • 14644421632 scopus 로고    scopus 로고
    • Development of a size dependent aerosol deposition model utilizing airway epithelial cells for evaluating aerosol drug delivery
    • Cooney D, Kazantseva M, and Hickey AJ: Development of a size dependent aerosol deposition model utilizing airway epithelial cells for evaluating aerosol drug delivery. Alter-nat Lab Anim. 2004;32:581-590.
    • (2004) Alter-nat Lab Anim , vol.32 , pp. 581-590
    • Cooney, D.1    Kazantseva, M.2    Hickey, A.J.3
  • 146
    • 51049084639 scopus 로고    scopus 로고
    • Inhalable siRNA: Potential as a therapeutic agent in the lungs
    • Durcan N, Murphy C, and Cryan SA: Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Phar-maceut. 2008;5:559-566.
    • (2008) Mol Phar-maceut , vol.5 , pp. 559-566
    • Durcan, N.1    Murphy, C.2    Cryan, S.A.3
  • 149
    • 77952503692 scopus 로고    scopus 로고
    • The failure of Exubera: Are we beating a dead horse?
    • Heinemann L: The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol 2008; 2: 518-529.
    • (2008) J Diabetes Sci Technol , vol.2 , pp. 518-529
    • Heinemann, L.1
  • 150
    • 0006619826 scopus 로고    scopus 로고
    • Pulmonary absorption and metabolism of peptides and proteins
    • RN Dalby, PR Byron, and SJ Farr (eds) Interpharm Press, Buffalo Grove, IL
    • Patton J, Nagarajan S, and Clark A: Pulmonary absorption and metabolism of peptides and proteins. In: RN Dalby, PR Byron, and SJ Farr (eds). Respiratory Drug Delivery VI. In-terpharm Press, Buffalo Grove, IL; pp. 17-24, 1998.
    • (1998) Respiratory Drug Delivery VI , pp. 17-24
    • Patton, J.1    Nagarajan, S.2    Clark, A.3
  • 151
    • 0026572056 scopus 로고
    • Pulmonary delivery of peptides and proteins for systemic action
    • Patton JS, and Platz RM: Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Del Rev. 1992;8:179-228.
    • (1992) Adv Drug Del Rev , vol.8 , pp. 179-228
    • Patton, J.S.1    Platz, R.M.2
  • 152
    • 0032754797 scopus 로고    scopus 로고
    • Injection related anxiety in insulin-treated diabetes
    • Zambanini A: Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-246.
    • (1999) Diabetes Res Clin Pract , vol.46 , pp. 239-246
    • Zambanini, A.1
  • 153
    • 0029085936 scopus 로고
    • Needle phobia: A neglected diagnosis
    • Hamilton JG: Needle phobia: a neglected diagnosis. J Fam Pract. 1995;41:169-175.
    • (1995) J Fam Pract , vol.41 , pp. 169-175
    • Hamilton, J.G.1
  • 154
    • 13144283137 scopus 로고    scopus 로고
    • Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem
    • Accessed July 3 2007
    • Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, and Edelman SV: Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Clin Dia-betes. 2004;22:147-150. http://www.nektar.com/wt/page/pr- 200312/?ref/IR- archived-press-releases. Accessed July 3 2007.
    • (2004) Clin Dia-betes , vol.22 , pp. 147-150
    • Polonsky, W.H.1    Fisher, L.2    Guzman, S.3    Villa-Caballero, L.4    Edelman, S.V.5
  • 155
    • 78650221998 scopus 로고    scopus 로고
    • Stanford Graduate School of Business Case Study #OIT-80;
    • Zenios S, Chess R, and Denend L: Exubera and NICE. Stanford Graduate School of Business Case Study #OIT-80; 2008.
    • (2008) Exubera and NICE
    • Zenios, S.1    Chess, R.2    Denend, L.3
  • 156
    • 36649030393 scopus 로고    scopus 로고
    • Inhaled insulin\gone with the wind?
    • Mathieu C, and Gale EAM: Inhaled insulin\gone with the wind? Diabetologia. 2008;51:1-5.
    • (2008) Diabetologia , vol.51 , pp. 1-5
    • Mathieu, C.1    Eam, G.2
  • 157
    • 34250749004 scopus 로고    scopus 로고
    • Pulmonary func-tion changes related to acute and chronic administration of inhaled insulin
    • Hegewald M, Crapo RO, and Jensen RL: Pulmonary func-tion changes related to acute and chronic administration of inhaled insulin. Diabetes Technol Therp. 2007; 9:S93-S101.
    • (2007) Diabetes Technol Therp , vol.9
    • Hegewald, M.1    Crapo, R.O.2    Jensen, R.L.3
  • 158
    • 1442275322 scopus 로고    scopus 로고
    • Glycemic exposure is associated with reduced pul-monary function in type 2 diabetes: The Freemantle diabetes study
    • Davis WA, Knuiman M, Kendall P, Grange V, and Davis TM: Glycemic exposure is associated with reduced pul-monary function in type 2 diabetes: the Freemantle diabetes study. Diabetes Care. 2004;27:752-757.
    • (2004) Diabetes Care , vol.27 , pp. 752-757
    • Davis, W.A.1    Knuiman, M.2    Kendall, P.3    Grange, V.4    Davis, T.M.5
  • 159
    • 33847635208 scopus 로고    scopus 로고
    • Disease progression modeling to characterize the effects of inhaled insulin (Exubera) on FEV1
    • French JL, Tensfeldt TG, Riese RJ, and Teeter JG: Disease progression modeling to characterize the effects of inhaled insulin (Exubera) on FEV1. Proc Am Thor Soc. 2006;3:A84.
    • (2006) Proc Am Thor Soc , vol.3
    • French, J.L.1    Tensfeldt, T.G.2    Riese, R.J.3    Teeter, J.G.4
  • 160
    • 78650192721 scopus 로고    scopus 로고
    • personal communication
    • Patton J, personal communication.
    • Patton, J.1
  • 161
    • 70349462771 scopus 로고    scopus 로고
    • Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12 month, ran-domized noninferiority trial
    • Ang E, Lawrence MK, Heilmann CR, Ferguson JA, Tobian JA, Webb DM, and Berclaz PY: Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: a 12 month, ran-domized noninferiority trial. Diabetes Technol Ther. 2009; 11:S35-S44.
    • (2009) Diabetes Technol Ther , vol.11
    • Ang, E.1    Lawrence, M.K.2    Heilmann, C.R.3    Ferguson, J.A.4    Tobian, J.A.5    Webb, D.M.6    Berclaz, P.Y.7
  • 163
    • 78650194013 scopus 로고    scopus 로고
    • http://www.ibtimes.com/articles/20080409/pfizer-nektar-exubera-insulin. htm
  • 167
    • 0031646537 scopus 로고    scopus 로고
    • Safety of inhaled proteins for therapeutic use
    • Wolff R: Safety of inhaled proteins for therapeutic use. J Aerosol Med. 1998;11:197-219.
    • (1998) J Aerosol Med , vol.11 , pp. 197-219
    • Wolff, R.1
  • 168
    • 25644437167 scopus 로고    scopus 로고
    • Dose response of inhaled dry powder insulin and dose equivalence to subcutaneous insulin Lispro
    • Rave KM, Nosek L, de la Pena A, Ernest CS 2nd, Heine-mann L, Batycky RP, and Muchmore DB: Dose response of inhaled dry powder insulin and dose equivalence to subcutaneous insulin Lispro. Diabetes Care. 2005;28:2400-2405.
    • (2005) Diabetes Care , vol.28 , pp. 2400-2405
    • Rave, K.M.1    Nosek, L.2    De La Pena, A.3    Heine-Mann, L.4    Batycky, R.P.5    Muchmore, D.B.6
  • 169
    • 70349462772 scopus 로고    scopus 로고
    • Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in pa-tients with type 2 diabetes previously treated with once daily insulin glargine
    • Rosenstock J, Eliaschewitz FG, Hellmann CR, Muchmore DB, Hayes RP, and Belin RM: Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in pa-tients with type 2 diabetes previously treated with once daily insulin glargine. Diabetes Technol Ther. 2009;11:S63-S73.
    • (2009) Diabetes Technol Ther , vol.11
    • Rosenstock, J.1    Eliaschewitz, F.G.2    Hellmann, C.R.3    Muchmore, D.B.4    Hayes, R.P.5    Belin, R.M.6
  • 170
    • 78650201586 scopus 로고    scopus 로고
    • AERx pulmonary drug deliv-ery systems
    • MJ Rathbone, J Hadgraft, MS Roberts, and ME Lane (eds)
    • Cipolla D, and Johansson E: AERx pulmonary drug deliv-ery systems. In: MJ Rathbone, J Hadgraft, MS Roberts, and ME Lane (eds). Modified Release Drug Delivery Technology, 2nd ed. pp. 563-571, 2008.
    • (2008) Modified Release Drug Delivery Technology, 2nd Ed , pp. 563-571
    • Cipolla, D.1    Johansson, E.2
  • 171
    • 0034043186 scopus 로고    scopus 로고
    • Pulmonary insulin adminis-tration using the AERx system: Physiological and physico-chemical factors influencing insulin effectiveness in healthy fasting subjects
    • Farr S, McElduff A, Mather L, Okikawa J, Ward ME, Gonda I, Licko V, and Rubsamen RM: Pulmonary insulin adminis-tration using the AERx system: physiological and physico-chemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther. 2000;2:185-197.
    • (2000) Diabetes Technol Ther , vol.2 , pp. 185-197
    • Farr, S.1    McElduff, A.2    Mather, L.3    Okikawa, J.4    Ward, M.E.5    Gonda, I.6    Licko, V.7    Rubsamen, R.M.8
  • 172
    • 78650206628 scopus 로고    scopus 로고
    • Pulmonary delivery of insulin using the asthma platform model
    • RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds) Amy Davis Biggs, River Grove, IL
    • Genova P, Buchwald A, McGovern M, et al.: Pulmonary delivery of insulin using the asthma platform model. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery IX. Amy Davis Biggs, River Grove, IL; pp. 537-539, 2004.
    • (2004) Respiratory Drug Delivery IX , pp. 537-539
    • Genova, P.1    Buchwald, A.2    McGovern, M.3
  • 173
    • 33745000699 scopus 로고    scopus 로고
    • Triple therapy in type 2 diabetes: Insulin glargine or rosglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
    • Rosenstock J, Sugimoto D, Strange P, Stewart JA, Solter-Rak E, and Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554-559.
    • (2006) Diabetes Care , vol.29 , pp. 554-559
    • Rosenstock, J.1    Sugimoto, D.2    Strange, P.3    Stewart, J.A.4    Solter-Rak, E.5    Dailey, G.6
  • 174
    • 16344387901 scopus 로고    scopus 로고
    • Patient outcomes in the GH monitor: The effect of delivery device on compliance and growth
    • Desrosiers P, O'Brien F, and Blethen S. Patient outcomes in the GH monitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005; 2(Suppl 3): 327-331.
    • (2005) Pediatr Endocrinol Rev , vol.2 , Issue.SUPPL. 3 , pp. 327-331
    • Desrosiers, P.1    O'Brien, F.2    Blethen, S.3
  • 178
    • 0028129568 scopus 로고
    • Effect of aero-solized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in pa-tients with cystic fibrosis
    • for the Pulmozyme Study Group
    • Fuchs HJ, Borowitz DH, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, and Wohl ME, for the Pulmozyme Study Group et al: Effect of aero-solized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in pa-tients with cystic fibrosis. N Engl J Med. 1994;331:637-642.
    • (1994) N Engl J Med , vol.331 , pp. 637-642
    • Fuchs, H.J.1    Borowitz, D.H.2    Christiansen, D.H.3    Morris, E.M.4    Nash, M.L.5    Ramsey, B.W.6    Rosenstein, B.J.7    Smith, A.L.8    Wohl, M.E.9
  • 180
    • 33947203155 scopus 로고    scopus 로고
    • Drying-induced variations in physico-chemical properties of amorphous pharmaceuti-cals and their impact on stability II: Stability of a vaccine
    • Abdul-Fattah AM, Truong-Le V, Yee L, Pan E, Ao Y, Ka-lonia DS, and Pikal MJ: Drying-induced variations in physico-chemical properties of amorphous pharmaceuti-cals and their impact on stability II: stability of a vaccine. Pharm Res. 2007;24:715-727.
    • (2007) Pharm Res , vol.24 , pp. 715-727
    • Abdul-Fattah, A.M.1    Truong-Le, V.2    Yee, L.3    Pan, E.4    Ao, Y.5    Ka-Lonia, D.S.6    Pikal, M.J.7
  • 181
    • 0037836974 scopus 로고    scopus 로고
    • Evaluation of novel aerosol formulations designed for mucosal vaccina-tion against influenza virus
    • Smith DJ, Bot S, Dellamary L, and Bot A: Evaluation of novel aerosol formulations designed for mucosal vaccina-tion against influenza virus. Vaccine. 2003;21:2805-2812.
    • (2003) Vaccine , vol.21 , pp. 2805-2812
    • Smith, D.J.1    Bot, S.2    Dellamary, L.3    Bot, A.4
  • 182
    • 42649090103 scopus 로고    scopus 로고
    • Safety evaluation of pulmonary influenza vaccination in healthy and asthmatic mice
    • Minne A, Huaux F, Jaworska J, Rha RD, Hamelmann E, and Vanbever R: Safety evaluation of pulmonary influenza vaccination in healthy and asthmatic mice. Vaccine. 2008;26:2360-2368.
    • (2008) Vaccine , vol.26 , pp. 2360-2368
    • Minne, A.1    Huaux, F.2    Jaworska, J.3    Rha, R.D.4    Hamelmann, E.5    Vanbever, R.6
  • 183
    • 43049120930 scopus 로고    scopus 로고
    • Development of stable influenza vaccine powder formulations: Challenges and possibilities
    • Amorij J-P, Huckriede A, Wilschut J, Frijlink HW, and Hinrichs WL: Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25:1256-1273.
    • (2008) Pharm Res , vol.25 , pp. 1256-1273
    • Amorij, J.-P.1    Huckriede, A.2    Wilschut, J.3    Frijlink, H.W.4    Hinrichs, W.L.5
  • 186
    • 33645467769 scopus 로고    scopus 로고
    • Ultrafine particle-lung interactions: Does size matter?
    • Kreyling WG, Semmler-Behnke M, and Moller W: Ultrafine particle-lung interactions: does size matter? J Aerosol Med. 2006;19:74-84.
    • (2006) J Aerosol Med , vol.19 , pp. 74-84
    • Kreyling, W.G.1    Semmler-Behnke, M.2    Moller, W.3
  • 187
    • 0035140471 scopus 로고    scopus 로고
    • Pulmonary effects of inhaled ultrafine particles
    • Oberdorster G: Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health. 2001;74:1-8.
    • (2001) Int Arch Occup Environ Health , vol.74 , pp. 1-8
    • Oberdorster, G.1
  • 189
    • 0034860506 scopus 로고    scopus 로고
    • Receptor-mediated targeting of spray-dried lipid particles co-formulated with lipid immunoglobulin loaded with a prototype vaccine
    • Bot AI, Smith DJ, Bot S, Dellamary L, Tarara TE, Harders S, Phillips W, Weers JG, and Woods CM: Receptor-mediated targeting of spray-dried lipid particles co-formulated with lipid immunoglobulin loaded with a prototype vaccine. Pharm Res. 2001;18:971-979.
    • (2001) Pharm Res , vol.18 , pp. 971-979
    • Bot, A.I.1    Smith, D.J.2    Bot, S.3    Dellamary, L.4    Tarara, T.E.5    Harders, S.6    Phillips, W.7    Weers, J.G.8    Woods, C.M.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.